Vertex Pharmaceuticals (VRTX) Exchanges $103.3M In Convertible Notes Into Common Stock
More News related to VRTX
- Vertex Pharma (VRTX) Announces Exercise of Over Allotment Option by Underwriters; Sees $500.5M in Gross Proceeds
- Vertex Pharmaceuticals Announces Exercise of Option by Underwriters of its Public Offering of Common Stock
- Leerink Swann Maintains an 'Outperform' on Vertex Pharmaceuticals (VRTX); Raises PT After Hosting Investor Meeting
- Vertex Pharma (VRTX) Prices 11.5M Shares at $38.50/Share
- Vertex Pharmaceuticals Announces Pricing of Public Offering of Common Stock
Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) said holders of its 4.75% Convertible Senior Subordinated Notes due 2013 have agreed to exchange approximately $103.3 million in aggregate principal amount of those notes for approximately 4.8 million shares of the Company's common stock, which is approximately 287,000 shares more than the number of shares into which the notes were convertible under their original terms.
Related Categories
Equity OfferingsStocks Mentioned
-0.59Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
